168 related articles for article (PubMed ID: 6628500)
1. Cardiocirculatory effects of moclobemide (Ro 11-1163), a new reversible, a short-acting MAO-inhibitor with preferential type A inhibition, in healthy volunteers and depressive patients.
Gasic S; Korn A; Eichler HG; Oberhummer I; Zapotoczky HG
Eur J Clin Pharmacol; 1983; 25(2):173-7. PubMed ID: 6628500
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: effects on hemodynamics and catecholamine metabolism in healthy volunteers.
Illi A; Sundberg S; Ojala-Karlsson P; Scheinin M; Gordin A
Clin Pharmacol Ther; 1996 Apr; 59(4):450-7. PubMed ID: 8612391
[TBL] [Abstract][Full Text] [Related]
3. Moclobemide, a new reversible MAO inhibitor--interaction with tyramine and tricyclic antidepressants in healthy volunteers and depressive patients.
Korn A; Eichler HG; Fischbach R; Gasic S
Psychopharmacology (Berl); 1986; 88(2):153-7. PubMed ID: 3081926
[TBL] [Abstract][Full Text] [Related]
4. Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A.
Da Prada M; Kettler R; Keller HH; Burkard WP; Muggli-Maniglio D; Haefely WE
J Pharmacol Exp Ther; 1989 Jan; 248(1):400-14. PubMed ID: 2783611
[TBL] [Abstract][Full Text] [Related]
5. Modification of the cardiovascular effects of ephedrine by the reversible monoamine oxidase A-inhibitor moclobemide.
Dingemanse J; Guentert T; Gieschke R; Stabl M
J Cardiovasc Pharmacol; 1996 Dec; 28(6):856-61. PubMed ID: 8961085
[TBL] [Abstract][Full Text] [Related]
6. Comparative investigation of the effect of moclobemide and toloxatone on monoamine oxidase activity and psychometric performance in healthy subjects.
Dingemanse J; Berlin I; Payan C; Thiede HM; Puech AJ
Psychopharmacology (Berl); 1992; 106 Suppl():S68-70. PubMed ID: 1546145
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of oral moclobemide in healthy human subjects and effects on MAO-activity in platelets and excretion of urine monoamine metabolites.
Wiesel FA; Raaflaub J; Kettler R
Eur J Clin Pharmacol; 1985; 28(1):89-95. PubMed ID: 3987791
[TBL] [Abstract][Full Text] [Related]
8. The effects of moclobemide on the pharmacokinetics of the 5-HT1B/1D agonist rizatriptan in healthy volunteers.
Van Haarst AD; Van Gerven JM; Cohen AF; De Smet M; Sterrett A; Birk KL; Fisher AL; De Puy ME; Goldberg MR; Musson DG
Br J Clin Pharmacol; 1999 Aug; 48(2):190-6. PubMed ID: 10417495
[TBL] [Abstract][Full Text] [Related]
9. Tyramine pressor response with moclobemide--a reversible monoamine oxidase inhibitor.
Tiller JW; Maguire KP; Davies BM
Psychiatry Res; 1987 Nov; 22(3):213-20. PubMed ID: 3432450
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A.
Burkard WP; Bonetti EP; Da Prada M; Martin JR; Polc P; Schaffner R; Scherschlicht R; Hefti F; Müller RK; Wyss PC
J Pharmacol Exp Ther; 1989 Jan; 248(1):391-9. PubMed ID: 2913284
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of monoamine oxidase by moclobemide: effects on monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers.
Koulu M; Scheinin M; Kaarttinen A; Kallio J; Pyykkö K; Vuorinen J; Zimmer RH
Br J Clin Pharmacol; 1989 Feb; 27(2):243-55. PubMed ID: 2469451
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the pressor effect of tyramine after treatment with phenelzine and moclobemide in healthy male volunteers.
Simpson GM; Gratz SS
Clin Pharmacol Ther; 1992 Sep; 52(3):286-91. PubMed ID: 1526086
[TBL] [Abstract][Full Text] [Related]
13. [Comparison of the new MAO-A inhibitors moclobemide, brofaromine and toloxatone with tranylcypromine in an animal experiment: significance for clinical practice].
Da Prada M; Keller HH; Kettler R
Psychiatr Prax; 1989 Aug; 16 Suppl 1():18-24. PubMed ID: 2587673
[TBL] [Abstract][Full Text] [Related]
14. Tolerability of moclobemide, a new reversible inhibitor of monoamine oxidase-A, compared with other antidepressants and placebo.
Versiani M; Nardi AE; Figueira IL; Stabl M
Acta Psychiatr Scand Suppl; 1990; 360():24-8. PubMed ID: 2123366
[TBL] [Abstract][Full Text] [Related]
15. Moclobemide, an inhibitor of MAO-A, does not increase daytime plasma melatonin levels in normal humans.
Scheinin M; Koulu M; Vakkuri O; Vuorinen J; Zimmer RH
Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(1):73-82. PubMed ID: 2300680
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the effects of moclobemide and selegiline on tyramine-evoked mydriasis in man.
Bitsios P; Langley RW; Tavernor S; Pyykkö K; Scheinin M; Szabadi E; Bradshaw CM
Br J Clin Pharmacol; 1998 Jun; 45(6):551-8. PubMed ID: 9663810
[TBL] [Abstract][Full Text] [Related]
17. Relationship between tyramine potentiation and monoamine oxidase (MAO) inhibition: comparison between moclobemide and other MAO inhibitors.
Zimmer R
Acta Psychiatr Scand Suppl; 1990; 360():81-3. PubMed ID: 2248084
[TBL] [Abstract][Full Text] [Related]
18. Potentiation of the pressor effect of intravenously administered tyramine during moclobemide treatment.
Zimmer R; Fischbach R; Breuel HP
Acta Psychiatr Scand Suppl; 1990; 360():76-7. PubMed ID: 2248082
[TBL] [Abstract][Full Text] [Related]
19. Pre-clinical pharmacology of moclobemide. A review of published studies.
Burkard WP; Da Prada M; Keller HH; Kettler R; Haefely W
Br J Psychiatry Suppl; 1989 Oct; (6):84-8. PubMed ID: 2695131
[TBL] [Abstract][Full Text] [Related]
20. Effect of a novel monoamine-oxidase inhibitor, moclobemide on the sensitivity to intravenous tyramine and norepinephrine in humans.
Cusson JR; Goldenberg E; Larochelle P
J Clin Pharmacol; 1991 May; 31(5):462-7. PubMed ID: 2050833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
